Abstract
Lung involvement in rheumatologic diseases has a broad spectrum of clinical and radiological presentations, from acute inflammatory to chronic, fibrosing predominance. For prognostic and therapeutic considerations a detailled work-up 'and optimally multidisciplinary evalution is needed, also to rule out other reasons for pulmonary deterioration such as infection (under immunosuppressive treatment) or pulmonary hypertension. For treatment guidance, several aspects need to be taken into consideration, such as disease severity, disease activity, clinical and radiological presentation, prognostic markers and comorbidities. Immunosuppressive treatment differs based on the type of rheumatologic diagnosis, although evidence for optimal therapy is rare in ILD associated with rheumatologic diseases.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
